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Tumor lysis syndrome (TLS) is rarely induces after Transarterial chemoembolization for hepatocellular
carcinoma. We present a patient with a large hepatocellular carcinoma who received twice transarterial
embolization (TAE). Tumor lysis syndrome was induced after the ﬁrst TACE in this patient. Due to the
previous experience, precautionary measures were taken before the second TAE. Therefore no compli-
cations were noted afterwards. We should be aware of tumor lysis syndrome, especially in high risk
patients.
Copyright © 2014, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. All rights reserved.1. Introduction burdens and/or rapidly dividing tumors, patients with a largeTumor lysis syndrome (TLS) is a rare but potentially lethal
complication that is induced after transarterial chemoembolization
for hepatocelluar carcinoma (HCC). Only a few cases have been
reported in the English-language literature. We present a patient
with a large HCC who twice underwent transarterial embolization
(TAE). To our knowledge, this is the ﬁrst time that different results
can be compared after the same patient had undergone two TAE
procedures. Tumor lysis syndromewas induced in this patient after
the ﬁrst transcatheter arterial chemoembolization (TACE). The pa-
tient's renal functions improved after various treatments such as
hemodialysis. Because of previous experience, precautionary
measures were performed before the second TAE. No complications
were noted afterwards. Physicians should be aware of TLS, espe-
cially in high-risk patients such as patients with large tumorthat all of my afﬁliations or
the foreseeable future, in any
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tric Emergency & Critical Care Menumber of ischemic areas within the tumor, patients with pre-
treatment renal dysfunction or volume depletion, and patients
with severe postembolization syndrome.2. Case report
A 65-year-old man had a past medical history of chronic hepa-
titis B and supraglottic cancer T3N0M0 post concurrent chemo-
radiation therapy; he had been in complete remission for 6 years.
Multiple hepatic tumors were detected during routine abdominal
ultrasonographic examination. No symptoms and signs such as
abdominal pain, weight loss, general malaise, tea-colored urine, or
jaundice were noted.
Laboratory data revealed a serum alpha-fetoprotein level of
1993.20 ng/dL; hemoglobin level of 12.5 g/dL; total leukocyte count
of 4600/mL; platelet level of 161,000/mL; international normalized
ratio (INR) of 1.31; serum total bilirubin level of 0.8 mg/dL; and
albumin level of 3.5 g/dL. As for his renal function, the levels of
blood urea nitrogen (21 mg/dL) and creatinine (1.3 mg/dL) were
slightly elevated. The levels of sodium (139 mEq/L), potassium
(3.7 mEq/L), and uric acid (6.9 mg/dL) were within normal limits.
The degree of hepatic dysfunction was Child's classiﬁcation A.
The abdominal ultrasound showed multiple hyperechoic
masses, primarily in the right lobe of the liver. Abdominal dynamic
computed tomography showed several nodular mass lesions
varying in size over the right lobe of the liver; the largest massdicine. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Dynamic computed tomography (CT) images. (A) On the arterial phase image of the dynamic CT, several markedly enhanced masses are present and vary in size with the
largest mass approximately 8.2 cm in diameter at S4 of the liver. The center of the tumor is not enhanced and is small necrotic tissue. (B) On the delayed-phase CT images, the tumor
shows hypoattenuation.
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(Fig. 1A and B). These tumors showed hypodensity on the precon-
trast ﬁlm, faint hyperdensity in the arterial phase image, and
hypodensity in the venous phase and delay-phase images. No evi-
dence of portal vein thrombosis was demonstrated. Based on the
laboratory data and various image ﬁndings, a diagnosis of HCC was
clinically made. The stage of the tumor was Barcelona Clinic Liver
Cancer (BCLC) stage B, Okuda stage II, Cancer of the Liver Italian
Program (CLIP) stage 3, and TNM stage IIIA.
Based on the tumor stage, surgery and radiofrequency ablation
did not seem applicable. In our institution, transarterial chemo-
embolization (TACE) is the ﬁrst recommended therapy for patients
with unresectable HCC. On June 22, 2012, the patient underwent
the ﬁrst TACE. Angiography revealed multiple hypervascular tu-
mors supplied by bilateral hepatic arteries in both lobes of the liver.
Therapeutic embolization was performed smoothly with mixed
lipiodol (20 mL) and doxorubicin (40 mg), followed by gelfoam
pieces and cephazolin at both hepatic arteries. Angiography ob-
tained immediately after the TACE showed adequate occlusion of
both hepatic arteries.Fig. 2. The computed tomography images after the ﬁrst transcatheter arterial che-
moembolization (TACE) demonstrate good response to TACE with dense lipiodol
retention. However, there is still marginal enhancement of the post-TACE lesion at S4
of the liver.On the third day after the TACE procedure, the patient had fever,
shortness of breath, and decreased urine output. Laboratory data
revealed markedly deteriorated renal function. The levels of blood
urea nitrogen (182 mg/dL), creatinine (15.2 mg), potassium
(6.5 mEq/L), uric acid (9.1 mg/dL), and phosphate (6.2 mg/dL) were
all markedly elevated. Hypocalcemia (7.1 mEq/L) was also noted.
Thus, TLS was strongly suspected because of the presence of severe
hyperuricemia, hyperkalemia, hypocalcemia, and acute renal fail-
ure, based on the CairoeBishop classiﬁcation system. Hydration by
intravenous ﬂuid infusion and hemodialysis were performed
immediately. The patient's renal functions improved and his urine
output progressively increased after the treatments. He was dis-
charged without any complications 19 days after the TACE
procedure.
The patient's renal function fully recovered approximately two
months after the ﬁrst TACE. Follow-up abdominal dynamic
computed tomography imaging demonstrated a good response to
TACE with dense lipiodol retention. However, there was still mar-
ginal enhancement of the post-TACE lesion at S4 on the arterial
enhancement image and decreased density on the delayed-phase
image (Fig. 2). Therefore, a second TAE was arranged for a sus-
pected residual hepatoma.
Because of previous experience, precautionary measures were
performed at the time of the second TAE to prevent TLS. Adequate
hydration by intravenous ﬂuid infusion and acetylcysteine were
administered before and after the second TAE. Superselective
therapeutic embolization of the right branch of the left hepatic
artery was performed smoothly using gelfoam pieces and cepha-
zolin. After the procedure, his renal functions and electrolytes were
all within normal limits. He was discharged 2 days after the second
TAE without any complications.
3. Discussion
To our knowledge, this is the ﬁrst time that different results can
be compared after two TAE procedures on the same patient. Pa-
tients with large tumor sizes or rapidly dividing tumors are usually
at greatest risk for TLS. There are other risk factors such as che-
mosensitive tumors; a large number of ischemic areas within a
tumor; high levels of serum potassium, phosphate, uric acid, lacate,
and lactate dehydrogenase; pretreatment renal dysfunction; and
volume depletion1-4. Other major complications of TACE besides
Tumor Lysis Syndrome After TACE 173TLS are liver dysfunction, severe postembolization syndrome, he-
patic infarction, biloma formation, liver abscess, tumor rupture,
septicemia, gastrointestinal bleeding, gallbladder infarction,
splenic infarction, pulmonary oil embolism, and spinal cord
injury1,5,6.
A higher frequency of acute TLS tends to occur with hemato-
logical malignancies with high proliferative fractions, large bulky
tumors such as Burkitt's lymphoma and other high grade non-
Hodgkin's lymphoma, and acute leukemia and chronic leukemia1.
However, other malignancies such as HCC, small-cell lung cancer,
breast cancer, seminoma, metastatic medulloblastoma, and meta-
static Meckel's cell tumor also reportedly cause TLS4,7e12. In our
patient, a bulky tumor with a large number of ischemic areas after
embolization and pretreatment renal dysfunction before the TAE
probably enhanced the likelihood of TLS after the treatment.
Transcatheter arterial chemoembolization rarely induces TLS. To
our knowledge, only a few cases have been reported in the English-
language literature13. In 1998, Burney ﬁrst reported two cases of
TACE-induced TLS, both of which involved large HCCs (greater than
5 cm)4. Besides TACE, TLS has also been reported to occur after
other treatments for HCC13 such as radiofrequency ablation14 and
oral thalidomide15.
We propose the following conclusions for why our patient had
different adverse effects after the two episodes of TAE. First, the area
of embolization between the two episodes varied greatly. In the ﬁrst
TACE, embolization was performed on both hepatic arteries,
whereas superselective therapeutic embolization of the right
branch of the left hepatic artery was performed for the second TAE.
The area of embolization may be a major factor in deciding whether
TLS will occur. Therefore, multiple TAEs should be arranged to
prevent the possibility of TLS in patients with multiple hepatic tu-
mors and pretreatment renal insufﬁciency. Second, adequate
intravenous ﬂuid hydration was not administered before and after
the ﬁrst TACE. The occurrence of post-TAE fever, TLS, and dehydra-
tion caused severe acute renal failure. Intravenous and oral N-ace-
tylcysteine may prevent contrast-mediumeinduced nephropathy in
patients treated with angioplasty16. Adequate hydration by intra-
venous ﬂuid infusion and acetylcysteine were prescribed before and
after the second TAE, thereby preventing TLS. Third, TACE with
doxorubicin (40 mg) was performed in the ﬁrst episode, whereas
TAE was performed in the second episode. It remains unclear
whether cytotoxicity, embolization, or both caused the metabolic
abnormalities of TLS. However, direct cytotoxicity and ischemic
necrosis of the tumor cells could have been contributing factors4.
According to themost recent European Association for the Study
of the Liver and European Organisation for Research And Treatment
of Cancer (EASL-EORTC) practice guidelines, chemoembolization is
recommended for patients with BCLC stage B, multinodular
asymptomatic tumors without vascular invasion or extra-hepatic
spread (EASL-EORTC 2012).22 However, the optimal method or
schedule remains undeﬁned and the contribution of chemotherapy
remains uncertain. Transcatheter arterial chemoembolization may
be associated with a higher response rate, compared to TAE alone.
However, the survival beneﬁt of TACE over TAE remains unproven.
The contribution of chemotherapy to the effectiveness of TACE has
been questioned because HCC is relatively chemoresistant. An
overall grade 3/4 toxicity occurred in 63.5% of individuals and in
83.7% of individuals in the TAE and TACE groups, respectively
(p ¼ 0.019)17. These severe constitutional adverse events and the
use of nephrotoxic agents such as chemotherapeutic drugs may
have a role in acute renal failure. Thus, we chose TAE as the sub-
sequent treatment option.
The management of TLS depends on anticipation, prevention,
and early recognition. In 2004, Cairo and Bishop deﬁned a classi-
ﬁcation system in which TLS is classiﬁed as “laboratory TLS” or“clinical TLS”. A 25% change or a level above or below normal levels
for any two or more serum values of uric acid (i.e., greater than
8 mg/dL), potassium (i.e., greater than 6 mEq/L), phosphate (i.e.,
greater than 4.5 mg/dL), and calcium (i.e., less than 7mg/dL) within
7 days after cancer therapy would be classiﬁed as laboratory TLS.
Laboratory TLS plus one or more of the following would be classi-
ﬁed as clinical TLS: increased serum creatinine (i.e., 1.5 times the
upper limit of normal), cardiac arrhythmia or sudden death, and
seizure18.
Therefore, close monitoring of renal functions and electrolytes
in high-risk patients are needed. When TLS develops, effective
treatments such as adequate hydration, oral medication (e.g.,
allopurinol and/or urate oxidase), or hemodialysis should be un-
dertaken immediately.
Transarterial chemoembolization (TACE) is effective for HCC;
however, acute renal failure developed in 12 (8.6%) of 140 patients
after TACE. The risk factors included the number of treatment
sessions; a ChildePugh class B classiﬁcation; and the development
of severe postembolization syndrome, which is characterized by
intermittent fever up to 38.1C, ischemic hepatitis, abdominal
pain, nausea, and loss of appetite19. Surgical resection is the
treatment of choice for early stage HCC. The perioperative com-
plications in elderly people receiving elective liver resection sur-
gery did not differ markedly from these complications in younger
patients. However, there was a higher incidence of postoperative
respiratory complications in elderly patients, as indicated by a
longer intubation time20.
Most cancers occur in adults who are older than 65 years, and
70% of all cancer deaths are in this population. The increase in
myeloproliferative and lymphoproliferative disorders and renal
senescence may have a role in TLS in elderly patients. Age-related
decreases in renin and aldosterone may contribute to an
increased risk of hyperkalemia. The pathophysiology of acute and
chronic renal failure in TLS involves many factors. Two major syn-
ergistic mechanisms are volume depletion and uric acid nephrop-
athy. Numerous drugs taken by elderly patients may increase the
risk of adverse drug interactions. Furthermore, many drugs can
elevate the serum uric acid level, which leads to an increased risk of
TLS. The management of TLS in elderly patients is often compli-
cated by deteriorating renal and heart function, the presence of
multiple comorbid conditions, polypharmacy, and difﬁculty in
adhering to a complex medication regimen21.
In conclusion, TAE-induced acute renal failure is common.
Physicians should beware of TLS, especially in high-risk patients
with large tumor burdens and/or rapidly dividing tumors, a large
number of ischemic areas within the tumor, pretreatment renal
dysfunction, volume depletion, and severe postembolization syn-
drome. Urine output, renal function, and electrolytes should be
monitored closely after the TAE. Nephrotoxic agents such as ami-
noglycosides and nonsteroidal anti-inﬂammatory drugs should be
avoided. If the clinical condition progresses to acute renal failure,
aggressive hemodialysis should not be delayed to prevent irre-
versible renal damage or prevent life-threatening complications.
The Institutional Review Board of the Mackay Memorial Hospital
approved this case report (14MMHIS095).
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